Top 12 Big Pharmas to outsource 100% of trial work says RPS CEO

By Gareth Macdonald

- Last updated on GMT

Related tags: Contract research organization

Twelve of the top 20 Big Pharmas could soon outsource 100 per cent of their clinical trial work using one of two strategic partnering models according to a speaker at contract research industry conference in Lyon, France yesterday.

The prediction by ReSearch Pharmaceutical Services (RPS) CEO Dan Perlman came on a busy first day of the Partnerships in Clinical Trials (PCT) Congress in a conference programme that was dominated by discussion of the pros and cons of various Pharma-CRO partnering models.

Perlman, who is chairman-elect of the US Association of Clinical Research Organizations (ACRO), put forward the case for strategic deals, describing alternatives like Functional Service Provider (FSP) models as high level staffing plays that do not allow Pharmas to reduce costly internal capabilities.

He was similarly forthright about Preferred Provider relationships, commenting that: “I have never seen one Big Pharma company keep a preferred provider for more than five years...they always seem to change providers when the opportunity arises​.”

Instead Perlman expects that in the near future most Big Pharmas will outsource development using either a programmatic model where trials are done by one or two partners or an embedded approach where CRO expertise is brought in-house and internal capability is shed.

The difference between the two models is control, Perlman continued, explaining that in the programmatic model the Pharma is reliant upon its partners’ operations whereas in the embedded model, initially, sponsor-developed mechanisms dominate before best practices are established.

He did voice some concerns about strategic partnerships particularly in relation to change order fees which he said were too often not factored in to cost estimates but was still confident that Pharmas using such models stand to make greater saving than those using other approaches.

Related news

Show more

Related products

show more


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Related suppliers